Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Novo Nordisk ( (NVO) ) just unveiled an announcement.
On 4 February 2026, Novo Nordisk launched a DKK 15 billion, 12‑month share repurchase programme, with a sub‑programme to buy back up to DKK 3.8 billion of B shares between 4 February and 4 May 2026. As of 6 March 2026, the company had repurchased 5,334,992 B shares for DKK 1,472,797,094, increasing its treasury stock to 22,724,791 B shares, or 0.5% of its share capital, underscoring its ongoing capital return strategy and confidence in its equity value.
Between 2 and 6 March 2026, Novo Nordisk executed daily buybacks of 250,000–265,000 B shares at average prices ranging from DKK 234.56 to DKK 251.23. The programme, disclosed in a 9 March 2026 filing, signals continued support for the share price and disciplined balance sheet management, with detailed transaction data made available to investors on the company’s website.
The most recent analyst rating on (NVO) stock is a Hold with a $41.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.
Spark’s Take on NVO Stock
According to Spark, TipRanks’ AI Analyst, NVO is a Neutral.
The score reflects strong underlying financial quality and attractive valuation, partially offset by a very weak technical setup (downtrend across all key moving averages) and a cautious near-term outlook from management, including guidance for declining 2026 sales and operating profit amid pricing and policy headwinds.
To see Spark’s full report on NVO stock, click here.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark, focused on defeating serious chronic diseases with a heritage in diabetes care. The company pioneers scientific breakthroughs, expands access to medicines, and works to prevent and ultimately cure disease, employing about 68,800 people in 80 countries and marketing its products in roughly 170 countries.
Average Trading Volume: 24,203,299
Technical Sentiment Signal: Sell
Current Market Cap: $169.8B
See more insights into NVO stock on TipRanks’ Stock Analysis page.